This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Amoureux, M.-C. Articles by Szathmary, S. Search for Related Content PubMed PubMed Citation Articles by Amoureux, M.-C. Articles by Szathmary, S. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Dialysis Kidney Failure Sepsis Social Bookmarking                         What's this?

A new method for removing endotoxin from plasma using hemocompatible affinity chromatography technology, applicable for extracorporeal treatment of septic patients

Clarigen Inc., Carlsbad, California, USA

Edit Hegyi

Clarigen Inc., Carlsbad, California, USA

Dzung Le

Clarigen Inc., Carlsbad, California, USA

Peter Grandics

Clarigen Inc., Carlsbad, California, USA

Hung Tong

Clarigen Inc., Carlsbad, California, USA

Susan Szathmary

Clarigen Inc., Carlsbad, California, USA

The pathogenesis of sepsis begins with the proliferation of micro-organisms at a site of infection, followed by invasion of the bloodstream and other organs. Gram-negative bacteria account for a large part of sepsis cases. The structural component of Gram-negative bacteria, endotoxin or lipopolysaccharide (LPS), induces the synthesis and release of endogenous mediators of sepsis. A growing number of investigations of the molecular mechanisms occurring in sepsis, point to endotoxin as a central mediator leading to multi-organ failure and death. In numerous clinical trials, attempts to target molecules downstream of endotoxin have been made, but have not been associated with improved survival. We describe an affinity-based system for the selective removal of endotoxin from plasma. The small-scale device, a 1.5 ml cartridge, contains beads that bind endotoxin with high specificity and efficiency. In addition, evidence is presented that this device does not affect plasma hemostasis, nor does it activate the complement system. Taken together, these results represent a proof of principle for endotoxin removal from plasma, which may be of clinical value to treat sepsis by extracorporeal circulation of the blood through a scaled-up version of this endotoxin-removing device.

Key Words: Endotoxin • plasma • hemocompatible affinity chromatography • extracorporeal treatment • septic patients

Journal of Endotoxin Research, Vol. 10, No. 2, 85-95 (2004)
DOI: 10.1177/09680519040100020401


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?